Key Details
Price
$6.68Annual ROE
-75.51%Beta
2.41Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Mar 14, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D.
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago.
Monte Rosa Therapeutics, Inc. ("Monte Rosa") announced the pricing of a public offering of its common stock and pre-funded warrants, with expected gross proceeds of approximately $100 million.
Monte Rosa Therapeutics (GLUE) passed our "Recent Price Strength" screen and may be an attractive option for investors seeking to capitalize on stocks showing momentum.
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
FAQ
- What is the ticker symbol for Monte Rosa Therapeutics?
- Does Monte Rosa Therapeutics pay dividends?
- What sector is Monte Rosa Therapeutics in?
- What industry is Monte Rosa Therapeutics in?
- What country is Monte Rosa Therapeutics based in?
- When did Monte Rosa Therapeutics go public?
- Is Monte Rosa Therapeutics in the S&P 500?
- Is Monte Rosa Therapeutics in the NASDAQ 100?
- Is Monte Rosa Therapeutics in the Dow Jones?
- When was Monte Rosa Therapeutics's last earnings report?
- When does Monte Rosa Therapeutics report earnings?
- Should I buy Monte Rosa Therapeutics stock now?